期刊文献+

肺血栓栓塞症患者抗凝治疗华法林用量与疗效个体差异的探讨 被引量:5

下载PDF
导出
摘要 目的介绍低分子肝素续贯华法林抗凝治疗患者华法林用量及达标天数的个体差异,探讨华法林如何合理使用。方法回顾性分析2009~2010年我院收治的肝素续贯华法林抗凝治疗急慢性肺栓塞患者47例抗凝达标时间、华法林剂量与年龄、性别、种族之间的关系。结果抗凝治疗患者总有效率93.62%,抗凝达标时间在维汉良民族间差异有统计学意义(P<0.05),华法林用量量维吾尔族明显大于汉族,无统计学意义(P>0.05);平均年龄差异无统计学意义(P<0.05);达到相同作用效果,高低剂量可相差6倍左右;抗凝达标时间相差10倍左右。结论华法林用量及疗效在维汉两民族间存在差异,且在同一民族不同个体间存在差异。
出处 《中国实用医药》 2012年第12期170-171,共2页 China Practical Medicine
  • 相关文献

参考文献4

  • 1Ansell J,Hirsh J,Poller L,et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126(3 Suppl):204s-233s.
  • 2Gage BF,Eby C,Milligan PE,et al.Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.Thromb Haemost,2004,91 (1):87-94.
  • 3Chenhsu RY,Chiang SC,Chou MH,et al.Long-term treatment with warfarin in Chinese population.Ann Pharmacother,2000,34(12):1395-1401.
  • 4胡荣,杜昕,马长生.华法林在房颤抗凝治疗中的应用[J].药物不良反应杂志,2004,6(6):366-368. 被引量:8

二级参考文献9

  • 1SPORTIF Ⅲ Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF Ⅲ): randomized controlled trial [J] .Lancet, 2003, 362(9397):1691.
  • 2Halperin JL. Efficacy and safety study of oral direct thromnin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation:SPORTIF V [C] . American Heart Associat
  • 3Kalta L, Yu G, Perez I, et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness [J] .BMJ, 2000, 320(7244):1236.
  • 4Economides Munoz C, Singh BN. Antithrombotic Therapies for stroke prevention fibrillation [J] . Minerva Cardioangiol, 2004, 52(2):125.
  • 5Ferro JM. Atrial fibrillation and cardioembolic stroke [J] . Minerva Cardiangiol, 2004, 52(2):111.
  • 6Anderson M, Kirk M. Anticoagulation in atrial fibrillation [J] . MedHealthR. I. 2004, 87(4):98.
  • 7Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: Facts and hypotheses [J] . Stroke, 1995, 26(8): 1471.
  • 8Lip GYH, Hart RG, Conway DSG. Antithrombotic therapy for atrial fibrillation [J] . BMJ, 2002, 325(7371):1022.
  • 9Gage BF, Boechler M, Doggette AL, et al. Adverse out comes and predictors ofunderuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation [J]. Stroke, 2000, 31(4):822.

共引文献7

同被引文献39

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部